Luminal breast cancer heterogeneity among women of different reproductive state


Cite item

Full Text

Abstract

The conducted research included 850 patients with breast cancer, treated in the FSBD «RNIOI» Ministry of Health RF in the period 2010-2013. Among them 649 had luminal tumors. According to our results their nature depend on menstrual state. The proprtion of the hormone-positive tumors prevails in all groups (p<0,05). In general, 76,4% against 23,6%. This is particularly evident in the group of menstruating women (79,8% against 20,2%). Luminal B subtype is the most common regardless menstrual state (59,9%). It’s also most expressed in the group of menstruating women, too (67,5%). However, the high level incidence of luminal B subtype in this group, unlike in perimenopausal women, is supported by higher level of Her2-neu overexpression or amplification associated with positive receptors (48,6% against 35,7%). In perimenopause, the level of luminal B is slightly lower than luminal A (55,9%). And in postmenopause it becomes higher again (58,1%), but due to the higher proliferative activity of tumors.

About the authors

O. I Kit

Rostov Scientific Research Institute of Oncology

344037, Rostov-on-Don, Russian Federation

Yuliana S. Shatova

Rostov Scientific Research Institute of Oncology

Email: shat5@rambler.ru
MD, Phd 344037, Rostov-on-Don, Russian Federation

S. S Todorov

Rostov Scientific Research Institute of Oncology

344037, Rostov-on-Don, Russian Federation

A. Je Lisutin

Rostov Scientific Research Institute of Oncology

344037, Rostov-on-Don, Russian Federation

T. N Gudtskova

Rostov Scientific Research Institute of Oncology

344037, Rostov-on-Don, Russian Federation

Je. Je Kechedzhieva

Rostov Scientific Research Institute of Oncology

344037, Rostov-on-Don, Russian Federation

References

  1. Семиглазов В.Ф. Стратегические и практические подходы к решению проблемы рака молочной железы. Вопросы онкологии. 2012; 58 (2): 148-52.
  2. Семиглазов В.Ф. Новые подходы к лечению рака молочной железы. Вопросы онкологии. 2013; 59 (3): 288-91.
  3. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J.A.M.A. 2006; 295:2492-502.
  4. Davis A.A., Kaklamani V.G. Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int. J. Breast Cancer. 2012; 10: Article ID 809291, doi: 10.1155/2012/809291.
  5. Kwan M.L., Kushi L.H., Weltzien E., Maring B., Kutner S.E., Fulton R.S. et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009; 11 (3): R31. (doi: 10.1186/bcr2261).
  6. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA. 2001; 98: 10869-74.
  7. Wo J.Y., Taghian A.G., Nguyen P.L., Raad R.A., Sreedhara M., Bellon J.R. et al. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int. J. Radiat. Oncol., Biol., Phys. 2010; 77: 188-96.
  8. Ignatiadis M., Sotiriou C. Luminal breast cancer: from biology to treatment. Nat. Rev. Clin. Oncol. 2013; 10(9): 494-506.
  9. Cheang M.C.U., Chia S.K., Voduc D., Gao D., Leung S., Snider J. et al. Ki 67 index, HER-2 status, and prognosis of patients with luminal B breast cancer. J. Nat. Cancer Inst. 2009; 101: 736-50.
  10. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 2009; 360(8): 790-800.
  11. Criscitiello C., Disalvatore D., Laurentiis M., Gelao L., Fumagalli L., Locatelli M. et al. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. Breast. 2014; (23): 69-75.
  12. Dowsett M., Nielsen T.O., A’Hern R., Bartlett J., Coombes R.C., Cuzick J. et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki-67 in Breast Cancer Working Group. J. Nat. Cancer Inst. 2011; 103: 1656-64.
  13. Bacchi L.M., Bacchi C.E., Carvalho F.M. Pathological and molecular characterization of breast carcinomas of young women. 2009: http://www.sbmastologia.com.br/revista%202009/19-02/pag%2042.pdf
  14. Сметник В.П., Тумилович Л.Г. Неоперативная гинекология. СПб.: Сотис; 1995.
  15. Romero Q., Bendahl P.-O., Klintman M., Loman N., Ingvar Ch., Ryden L. Ki-67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies. BMC Cancer. 2011; 11: 341.
  16. Kurian A.W., Fish K., Shema S.J., Clarke C.A. Lifetime risks of specific breast cancer subtypes among women in four racial/ ethnic groups. Breast Cancer Res. 2010; 12(l): R99.
  17. Bacchi L.M., Corpa M., Santos P.P., Bacchi C.E., Carvalho F.M. Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: A pathological and immunohistochemical study. Breast. 2010; 19: 137-41.
  18. Durbecq V., Ameye L., Veys I., Paesmans M., Desmedt C., Sirtaiine N. et al. A significant proportion of elderly patients develop hormone-dependent “luminal-B’ tumors associated with aggressive characteristics. Crit. Rev. Oncol. Hematol. 2008; 67: 80-92.
  19. Кит О.И, Франциянц Е.М., Бандовкина В.А., Шатова Ю.С., Комарова Е.Ф., Верескунова М.И. и др. Содержание метаболитов эстрона в периферических жидкостях и тканях у женщин, больных раком молочной железы, разного возраста и репродуктивного статуса. Фундаментальные исследования. 2013; 7(2): 319-23.
  20. Кит О.И. Франциянц Е.М., Бандовкина В.А., Шатова Ю.С., Комарова Е.Ф., Верескунова М.И. и др. Уровень половых гормонов и пролактина в ткани злокачественных опухолей молочной железы у больных разного возраста. Фундаментальные исследования. 2013; 7(3): 560-4.
  21. Бандовкина В.А., Франциянц Е.М., Шатова Ю.С. Верескунова М.И., Кучкина Л.П. Уровень метаболитов эстрона в крови, моче и опухолевой ткани у переменопаузальных и постменопаузальных больных раком молочной железы. В кн.: Материалы VIII Всероссийского съезда онкологов (Санкт- Петербург. 11-13 сент. 2013 г.). Том I. Вопросы онкологии. 2013; 59 (3, прил.): 31.
  22. Бандовкина В.А., Франциянц Е.М., Шатова Ю.С., Верескунова М.И., Кучкина Л.П. Уровень половых гормонов и пролактина в опухолевой и перифокальной зоне при раке молочной железы у женщин в пре- и постменопаузальный период. В кн.: Материалы VIII Всероссийского съезда онкологов (Санкт-Петербург. 11-13 сент. 2013 г.). Том I. Вопросы онкологии. 2013; 59 (3, прил.): 250.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies